Covenant Partners’s Core Laboratories CLB Stock Holding History

Covenant Partners’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,650	Closed	-$389K	–	192
2019 Q1	$389K	Buy	+5,650	New	+$379K	0.22%	117

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Covenant Partners's CLB Position: Q2 2019 in Review

Covenant Partners sold out of Core Laboratories (CLB) in Q2 2019, closing a stake of 5,650 shares — an estimated $389K sold.

Covenant Partners first reported a position in CLB in Q1 2019 and held it in 1 quarter. The position peaked at $389K in Q1 2019. 304 funds tracked by Wall St. Rank hold CLB as of Q2 2019.

Covenant Partners reported no remaining Core Laboratories position as of Q2 2019 after selling out during the quarter.
Covenant Partners sold 5,650 Core Laboratories shares in Q2 2019, an estimated $389K.
Covenant Partners first reported a position in Core Laboratories in Q1 2019 and held it in 1 quarter.
Covenant Partners's Core Laboratories position peaked at $389K in Q1 2019.
304 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2019.

Based on Covenant Partners's 13F filing for Q2 2019, filed 15 Aug 2019.